Inverse fluoxetine effects on inhibitory brain activation in non-comorbid boys with ADHD and with ASD

Kaylita Chantiluke · Nadia Barrett · Vincent Giampietro · Paramala Santosh · Michael Brammer · Andrew Simmons · Declan G. Murphy · Katya Rubia

Received: 1 November 2013 / Accepted: 3 December 2014 / Published online: 24 December 2014 © The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract
Rationale Attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) are often comorbid and have both performance and brain dysfunctions during motor response inhibition. Serotonin agonists modulate motor response inhibition and have shown positive behavioural effects in both disorders.

Aims We therefore used functional magnetic resonance imaging (fMRI) to investigate the so far unknown shared and disorder-specific inhibitory brain dysfunctions in these two disorders, as well as the effects of a single dose of the selective serotonin reuptake inhibitor fluoxetine.

Methods Age-matched boys with ADHD (18), ASD (19) and healthy controls (25) were compared with fMRI during a stop task measuring motor inhibition. Patients were scanned twice, under either an acute dose of fluoxetine or placebo in a double-blind, placebo-controlled randomised design. Repeated measures analyses within patients assessed drug effects. To test for potential normalisation effects of brain dysfunctions, patients under each drug condition were compared to controls.

Results Under placebo, relative to controls, ASD boys showed overactivation in left and right inferior frontal cortex (IFC), while ADHD boys showed disorder-specific underactivation in orbitofrontal cortex (OFC) and basal ganglia. Under fluoxetine, the prefrontal dysfunctions were no longer observed, due to inverse effects of fluoxetine on these activations: fluoxetine downregulated IFC and OFC activation in ASD but upregulated them in ADHD.

Conclusions The findings show that fluoxetine normalises frontal lobe dysfunctions in both disorders via inverse effects, downregulating abnormally increased frontal activation in ASD and upregulating abnormally decreased frontal activation in ADHD, potentially reflecting inverse baseline serotonin levels in both disorders.

Keywords ADHD · ASD · Motor response inhibition · Stop task · fMRI · Serotonin · Fluoxetine

Introduction
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder defined by age-inappropriate levels of inattention, impulsivity and hyperactivity (American Psychiatric Association 2000). Autism spectrum disorder (ASD) is defined by impairments in communication, social interaction and by restricted and repetitive behaviours (American Psychiatric Association 2000). There is increasing evidence for comorbidity between disorders (Rommelse et al. 2011; Simonoff et al. 2008; van der Meer et al. 2012) and shared executive function deficits (Corbett et al. 2009; Geurts et al. 2004), in particular in motor response inhibition.
neurotransmitter underpinnings of these cognitive abnormalities is whether SE modulates the inhibitory network in both ADHD and ASD and whether this modulation differs between disorders.

The aim of this fMRI study was therefore to investigate (1) shared and disorder-specific brain dysfunctions in ADHD and ASD boys during a tracking stop task and (2) shared and disorder-specific neurofunctional effects of an acute dose of fluoxetine on these inhibitory (dys)functions in both disorders. It has been argued that inferior frontal activation during stop task performance may be confounded by the attentional odd-ball effect of the low frequency appearance of stop signals (Hampshire et al. 2010; Pauls et al. 2012a). Given that in this study we were particularly interested in the effects of fluoxetine on inhibitory rather than on attention networks, in our fMRI analysis we contrasted successful stop trials with failed stop trials in order to control for the attentional oddball effect of the low frequency appearance of the stop trials.

We hypothesised that, under placebo, ADHD boys compared to controls would show decreased IFC and caudate activation (Cortese et al. 2012; Cubillo et al. 2012; Cubillo et al. 2014; Hart et al. 2013; Rubia et al. 1999; Rubia et al. 2005b), whereas ASD boys would show increased left frontal activation (Schmitz et al. 2006). We further hypothesised that fluoxetine compared to placebo, given its beneficial effects on symptoms, would normalise the abnormal activations in each disorder, i.e. it would increase the reduced fronto-striatal activation in ADHD, but reduce the increased left frontal abnormalities in ASD.

Materials and methods

Participants

Sixty-two right-handed boys (Edinburgh Handedness Inventory) (Oldfield 1971) (25 controls, 18 with ADHD and 19 with ASD) aged 10–17, IQ>70 (Wechsler Abbreviated Scale of Intelligence-Revised (WASI-R) (Wechsler 1999) participated in this study.

ADHD boys had a clinical diagnosis of non-comorbid ADHD, inattentive/hyperactive-impulsive combined subtype, as assessed by an experienced child psychiatrist using the standardised Maudsley diagnostic interview that assesses ADHD according to DSM-IV criteria (Goldberg and Murray 2006). They scored above clinical threshold for ADHD symptoms on the Strengths and Difficulties Questionnaire (SDQ) (Goodman and Scott 1999) and the Conners’ Parent Rating Scale-Revised (CPRS-R) (Conners et al. 1998). Four of the ADHD boys were medication-naïve, three had ceased taking methylphenidate for a year (1), or 3 months (2) and 11 received chronic stimulants, but had a 48-h medication washout prior to scanning. ADHD boys were excluded if they scored
above 15 on the Social Communication Questionnaire (SCQ) (Rutter et al. 2003).

ASD diagnosis was made using ICD-10 (World Health Organisation (WHO) 1994) diagnostic criteria and confirmed by the Autism Diagnostic Interview-Revised (ADI–R) (Lord et al. 1994) and the Autism Diagnostic Observation Schedule (ADOS) (Lord et al. 2000). All ASD subjects were medication-naive apart from one patient, who took melatonin (but underwent a 2-week medication washout). ASD exclusion criteria included a score above 7 on the hyperactivity/inattention subscale of the SDQ or a t score above 70 on the DSM-IV subscale of the CPRS-R.

Exclusion criteria for all were comorbidity with other psychiatric or neurological disorders and drug/alcohol dependency. Patients were recruited from local clinics and support groups.

Patients were scanned twice in a double-blind, randomised, placebo-controlled design, using a Latin square randomization design for counter-balanced effects. Due to the half-life of fluoxetine (1–3 days) and its metabolite norfluoxetine (5–16 days) (Wong et al. 1995), each scan was 3–4 weeks apart. To ensure that fluoxetine had reached its peak plasma levels, after 5–8 h (Wong et al. 1995), patients were scanned 5 h after administration. Liquid fluoxetine was titrated to age and weight (see supplement). Placebo was equivalent amounts of peppermint water with similar taste to fluoxetine.

Twenty-five healthy, handedness and age-matched boys were recruited by advertisement and scored below clinical thresholds on the SDQ, SCQ and CPRS.

Participants gave written informed consent/assent. The study was approved by the local Ethics Committee. Participants were paid £50 for each scan.

For recruitment, demographic and clinical details of participants, see Table 1.

FMRI paradigm: stop task

Subjects practised the task once prior to each scan under supervision of the researcher who made sure the participants understood the task and performed accordingly (by inhibiting more or less 50 % of trials). The 8 min 49 s minute visual tracking stop task requires withholding of an already triggered motor response to a go stimulus when it is followed unpredictably by a stop signal (Cubillo et al. 2014; Rubia et al. 2011; Rubia et al. 2003; Rubia et al. 2005b; Rubia et al. 2007). Subjects have to respond as quickly as possible to left or right pointing “go” arrows (500 ms duration, 80 % of 294 trials) with a left or right (thumb) button press, followed by a gap of 1100 to 1500 ms (which makes up a mean trial length of 1.8 s; jittered between 1.6 and 2 s to optimise statistical efficiency). In 20 % of trials (60), pseudo-randomly interspersed, and at least 3 repetition times apart for adequate separation of the hemodynamic response, go signals are followed (about 250 ms later) by arrows pointing upwards (300 ms duration) (stop signals), and subjects have to inhibit their motor response. A tracking algorithm changes the time interval between go and stop-signal onsets according to each subject’s inhibitory performance, which is recalculated after each stop signal based on the average percentage of inhibition over previous stop trials to provide 50 % successful and 50 % unsuccessful inhibition trials (Supplementary Figure S1).

Given that the contrast of stop-go trials is confounded by the attentional oddball effect of the low frequency of stop trials (20 %) relative to go trials (80 %), which also activates IFC (Hampshire et al. 2010; Pauls et al. 2012b), for the fMRI analysis, brain activation to the 50 % unsuccessful stop trials was subtracted from the 50 % successful stop trials, controlling for the attentional oddball effect of the infrequent stop signal appearance.

The dependent inhibition variable is the stop signal reaction time (SSRT), calculated by subtracting the mean stop signal delay (SSD: the average time between go and stop signal at which the subject managed to inhibit to 50 % of trials) from the mean reaction time (MRT) to go trials, i.e. MRT-SSD (Logan et al. 1997). MRT, intrasubject standard deviation of MRT, and omission error percentage are variables of the executive process of the task.

Data analysis

Analysis of performance data

MANOVAs compared performance variables between controls and the two patient groups under placebo and between controls and the two patient groups under fluoxetine. Multiple repeated-measures ANOVAs within the two patient groups with group (ADHD, ASD) as independent factor and drug condition (placebo/fluoxetine) as repeated measures were conducted to test for group by medication interaction effects on performance.

FMRI image acquisition

Gradient-echo echoplanar MR imaging (EPI) data were acquired on a General Electric Signa 3T Horizon HDx system at the Centre for Neuroimaging Sciences, Institute of Psychiatry, King’s College London, UK. A semiautomated quality control procedure ensured consistent image quality. A quadrature birdcage headcoil was used for RF transmission and reception. In each of 28 non-contiguous planes parallel to the anterior–posterior commissure, 296 T2*-weighted MR images depicting BOLD contrast covering the whole brain were acquired with TE=30 ms, TR=1.8 s, flip angle=75°, in-plane voxel-size=3 mm, slice thickness=5.5 mm and slice-skip=
A whole-brain high-resolution structural scan (inversion recovery gradient echo planar image) on which to superimpose the individual activation maps, was also acquired in the inter-commissural plane with TE=30 ms, TR=3 s, flip angle=90°, 43 slices, slice thickness=3.0 mm, slice skip=0.3 mm and in-plane voxel-size=1.875 mm.

All subjects performed three other fMRI tasks which are not reported here.

FMRI image analysis

The XBAM software package was used (http://www.brainmap.co.uk/) (Brammer et al. 1997) which makes no normality assumptions (often violated in fMRI data), but instead uses median statistics to control outlier effects and permutation rather than normal theory-based inference (Thirion et al. 2007).

Individual- and group-level analyses are described in further detail elsewhere (Brammer et al. 1997; Cubillo et al. 2014; Rubia et al. 2003; Rubia et al. 2005b; Rubia et al. 2007) and in the supplementary material. Briefly, the fMRI data were realigned to minimise motion-related artefacts and smoothed using a Gaussian filter (FWHM 8.82 mm) (Bullmore et al. 1999a). Further data analysis included slice timing correction and the residual effects of motion were regressed out from the time series (using the estimated motion parameters) before fitting a general linear model. Time-series analysis of individual subject activation was performed with a wavelet-based resampling method previously described (Bullmore et al. 2001). We convolved the task epoch of the contrasts of interest (i.e. successful stop—implicit go trials; failed stop trials—implicit go trials) and the higher level contrast (successful stop-go trials minus unsuccessful stop-go trials) with two Poisson model functions (delays of 4 and 8 s). Individual activation maps were recalculated by testing the goodness-of-fit of this convolution with the BOLD time series; the goodness-of-fit calculation used the ratio of the sum of squares of deviations from the mean intensity value due to the model (fitted time series) divided by the sum of squares due to the residuals (original time series minus model time series). This statistic, the sum of squares (SSQ) ratio, was used in further analyses. Using rigid body and affine transformation, the individual maps were registered into Talairach standard space. A group brain activation map was then produced for each medication condition and each experimental condition (see supplementary material).

ANOVA between-group difference analyses

For between-group comparisons between controls and patients under either placebo or fluoxetine, one-way ANCOVA analyses with group as factor and rotational and translation movement in Euclidian 3-D space as covariate, were conducted using randomization-based tests for voxel or cluster-wise differences as described in detail elsewhere (Bullmore et al. 2001; Bullmore et al. 1999b). For these between-group comparisons, less than one false activated cluster was expected at \( p < 0.05 \) for voxel and \( p < 0.01 \) for cluster comparisons. Given that right IFC was an a priori hypothesised region, we used a more lenient cluster level threshold of \( p < 0.05 \) and also

### Table 1: Sample characteristics for healthy control boys and patients with ADHD and ASD

| Variables                                | Controls (25) mean (SD) | ADHD (18) mean (SD) | ASD (19) mean (SD) |
|------------------------------------------|-------------------------|---------------------|--------------------|
| Age (years)                              | 13.4 (2.4)              | 14.3 (1.8)          | 14.7 (2.0)         |
| IQ                                       | 109 (13)                | 95 (11)             | 112 (15)           |
| SDQ hyperactive-impulsive/inattentive subscale | 1.8 (1.6)              | 9.2 (0.9)           | 4.5 (1.8)          |
| SDQ—emotional distress subscale          | 0.5 (0.8)               | 3.6 (3.0)           | 4.2 (3.0)          |
| SDQ—conduct subscale                     | 0.3 (0.7)               | 5.0 (2.4)           | 2.1 (2.0)          |
| SDQ—peer relations subscale              | 0.6 (1.1)               | 3.4 (2.5)           | 6.1 (2.4)          |
| SDQ—prosocial behaviour subscale         | 9.1 (1.3)               | 6.7 (2.3)           | 5.1 (2.3)          |
| SDQ—total scores                         | 3.3 (2.9)               | 21.2 (4.9)          | 16.8 (5.7)         |
| SCQ total                                | 1.6 (2.7)               | 7.0 (3.4)           | 23.5 (5.5)         |
| CPRS-R total T score                     | 44 (3)                  | 83 (7)              | 57 (8)             |
| ADOS communication scores                | —                       | —                   | 2 (1)              |
| ADOS social interaction scores            | —                       | —                   | 7 (4)              |
| ADOS communication and social scores      | —                       | —                   | 9 (5)              |
| ADOS stereotyped behaviour scores         | —                       | —                   | 1 (1)              |
| ADI communication scores                  | —                       | —                   | 14 (4)             |
| ADI social interaction scores             | —                       | —                   | 17 (5)             |
| ADI stereotyped scores                   | —                       | —                   | 6 (3)              |
Conducted a region of interest analysis using the IFC as a mask. Then the standardised BOLD response values for each participant were extracted for the significant clusters of the ANCOVA analyses and post hoc t-tests (correcting for multiple comparisons using least significant difference (LSD)) were conducted to identify the direction of the group differences.

ANCOVA within-patient interaction effects

A 2×2 ANCOVA (2 medication conditions, 2 groups) with rotational and translation movement as covariate was conducted using randomised-based testing for voxel or cluster-wise differences as described elsewhere (Bullmore et al. 2001). Less than one false positive activation cluster was expected at $p<0.05$ at voxel and $p<0.01$ at cluster level. For our a priori hypothesised region in right IFC, a more lenient $p<0.05$ was used as well as a region of interest analysis using the IFC as a mask. Statistical measures of BOLD response for each participant were then extracted in each of the significant clusters and post hoc t tests (corrected for multiple comparisons with LSD) were conducted to identify the direction of the interaction effects.

Results

Participant characteristics

ANOVARs showed no significant group differences in age ($F$ (df=2,61)=3; n.s.) but in IQ ($F$ (df=2,61)=10, $p<0.001$) which was significantly lower in ADHD relative to control and ASD boys ($p<0.005$), who did not differ. Given that ADHD children have typically lower IQ than their healthy peers (Bridgett and Walker 2006), data were not covaried for IQ, as covarying for a measure that is associated with the condition would violate ANCOVA assumptions (Dennis et al. 2009). Nonetheless, to assess the potential impact of IQ, analyses were repeated with IQ as covariate. For group differences in clinical measures, see Table 1.

Performance data

As expected, all subjects achieved approximately 50% probability of inhibition, suggesting the algorithm was successful and there were no differences between controls and patient groups in this measure for either placebo ($F$ (df=2,61)=1.2; $p=n.s.$) nor fluoxetine ($F$ (df=2,61)=2.7, $p=n.s.$) nor were there any group or group by medication interaction effects for the within-patients analysis ($F$ (df=2,61)<1, $p=n.s.$). MANOVA showed a trend for a significant group effect for placebo ($F$ (df=8,114); $p<0.08$), which was due to increased omission errors between controls and patients under placebo ($F$ (df=2,61)=4, $p<0.02$). Post hoc analyses (corrected for multiple testing using least significance difference (LDS)) showed that this was due to ADHD boys having increased omission errors than both control ($p<0.05$) and ASD boys ($p<0.01$) (Table 2). MANOVA for fluoxetine showed no significant group effect ($F$ (df=2,61)=1.2, $p=n.s.$).

Within the patient groups there were no significant group (df=1,35) or group by medication interaction effects (df=1, 35) for any variables ($F<1$ for all measures).

Given that ADHD patients performed the task twice, but controls only once, we also measured practice effects in the ADHD group using repeated measures t tests between performance measures at scans 1 and 2. No significant differences were found ($F$ (df=1,17)=0.02, $p=n.s.$).

FMRI data

Movement

The Euclidean formula described below was used to produce a 3-D movement value known as $d$ which is representative of movement in $x$, $y$ and $z$. The formula was used to produce a $d$ value for the maximum translation and maximum rotation of each participant.

$$d = \sqrt{(p_1-q_1)^2 + (p_2-q_2)^2 + (p_3-q_3)^2}.$$

Repeated measures ANOVARs showed no significant group by movement interaction effects in the Euclidean measures of maximum xyz rotation ($F$ (df=4118)=2, $p=0.14$) or maximum xyz translation ($F$(df=4118)=1, $p=0.58$). Nevertheless, to eliminate any potential effects of non-significant variance in motion, these Euclidean motion parameters for maximum xyz translation and rotation were used as covariates in the fMRI analyses.

Within-group activations are reported in the supplementary results section and in supplementary Figs. S2 and S3.

Between-group differences between controls and patients under placebo

ANOVAR between controls and patients on placebo showed significant group differences in left middle/IFC, left OFC/ superior temporal lobe (STL) reaching into putamen and globus pallidus and in left inferior parietal lobe (IPL). The hypothesised difference in right IFC was observed at a more lenient $p<0.05$ (Fig. 1a, Table 3) and confirmed by a region of interest analysis (Talairach coordinates (x;y;z)=54;7;26; BA 45; 10 voxels).
Post hoc analyses showed that the group effect in right IFC was due to significantly increased activation in ASD relative to control boys \((p<0.005)\) and trend-wise compared to ADHD boys \((p<0.08)\). In left middle/IFC, ASD patients had

| Performance measure | Controls Mean SD | ADHD placebo Mean SD | ADHD fluoxetine Mean SD | ASD placebo Mean SD | ASD fluoxetine Mean SD |
|---------------------|-----------------|----------------------|------------------------|---------------------|------------------------|
| SSRT                | 161 107         | 132 81               | 142 109                | 140 125             | 142 103                |
| PI                  | 51 3            | 50 3                 | 49 4                   | 50 3                | 49 4                   |
| SSD                 | 462 23          | 497 27               | 490 30                 | 479 27              | 480 29                 |
| MRT to go trials    | 623 104         | 629 86               | 632 109                | 618 102             | 622 113                |
| SD for MRT to go trials | 174 39        | 194 44               | 194 60                 | 168 39              | 166 43                 |
| Omission errorsa    | 5 5             | 9 8                  | 9 9                    | 3 5                 | 3 3                    |

\(PI\) percentage inhibition, SSRT stop signal reaction time, SSD average stop signal delay, MRT mean reaction time SD = intrasubject variability of reaction time (in ms)

\(a\) ADHD > C, ASD

---

For the stop task, Table 2 includes measures such as SSRT (Stop Signal Reaction Time), PI (Percentage Inhibition), SSD (Average Stop Signal Delay), MRT to go trials, and SD for MRT to go trials. The table also provides mean and standard deviation values for these measures across different groups (Controls, ADHD placebo, ADHD fluoxetine, ASD placebo, ASD fluoxetine).

---

**Fig. 1** Between-group brain activation differences between controls and patients under placebo or fluoxetine for the contrast of successful stop with unsuccessful stop trials. **A** Axial sections showing the between-group ANCOVA comparison findings between controls and patients under placebo. Shown underneath are the statistical measures of BOLD response for each of the three groups for each of the brain regions that showed a significant group effect. **B** Axial sections for the between-group ANCOVA comparison between controls and patients under fluoxetine. Talairach z coordinates are indicated for slice distance (in mm) from the intercommissural line. The right side of the image corresponds to the right side of the brain.
significantly increased activation compared to both control and ADHD boys \((p<0.005)\) who activated this region during failed inhibition and had a trend-wise reduction relative to controls \((p<0.08)\). In left OFC/STL/basal ganglia both control and ASD boys, who did not differ from each other, showed increased activation relative to ADHD boys who activated this area during failed inhibition \((p<0.005)\). Left IPL was significantly reduced in both patient groups relative to controls \((p<0.05)\), with ASD patients activating this area significantly more during failed inhibition than ADHD \((p<0.05)\).

To test whether group effects were related to task performance, we correlated all clusters with SSRT and omission errors, since they were lower in ADHD relative to controls. The (reduced) activation in left OFC/basal ganglia in ADHD was significantly negatively correlated with omission errors \((r=-0.5, p<0.05)\). No other correlations were significant.

Between-group differences between controls and patients under fluoxetine

There were significant group differences in bilateral pre-SMA/superior frontal cortex, SMA proper, left IPL/middle temporal lobe, right IPL and precuneus (Fig. 1b, Table 3). Post hoc analyses showed that control and ASD boys, who did not differ, activated pre-SMA/superior frontal cortex significantly more during successful inhibition than ADHD boys who activated this cluster more during failed inhibition \((p<0.0001)\). SMA proper was significantly more activated in patients, who did not differ relative to controls, who activated this region more during failed inhibition \((p<0.05)\). In bilateral IPL, controls and ASD boys had increased activation during successful inhibition relative to ADHD boys who activated this region more during failed inhibition \((p<0.05)\). In right IPL, ASD boys also had increased activation relative to controls \((p<0.05)\). In precuneus, ADHD boys showed significantly enhanced activation for successful inhibition relative to both ASD \((p<0.05)\) and controls who activated this region during failed inhibition and differed relative to ASD \((p<0.05)\). Correlations with behaviour showed that activation in pre-SMA/superior frontal cortex during successful inhibition was negatively correlated with SSRT in the ASD group \((r=-0.532, p<0.05)\). Activation in precuneus was negatively correlated with SSRT in the ADHD group \((r=-0.493, p<0.05)\).

Effect size comparisons of case-control conditions to test for significant “normalisation” effects

To establish whether the group differences between controls and patients under each drug condition (ADHD/ASD under placebo versus controls; ADHD/ASD under fluoxetine versus controls) were significantly different, we directly compared the effect sizes (ES) of the group differences from the two case-control comparisons (Matthews and Altman 1996).

When comparing two effect sizes, the \(z\) test can evaluate the likelihood of whether they are significantly heterogeneous. The difference between the two effect sizes can be considered a normalized variable, where the standard error of the difference is a combination of the standard errors of the two comparisons. Based upon this, the probability of a type I error can be calculated using the formula: \(p (\alpha) = (\text{es}_1 - \text{es}_2)/\sqrt{(\text{se}_1^2 + \text{se}_2^2)}\).

For the abnormalities in the ADHD patients, the effect sizes of the ADHD placebo-control contrast was not significantly different from the effect sizes of the ADHD fluoxetine-control comparison for left OFC \((z=-0.9, p=\text{n.s.})\), right IFC \((z=-0.6; p=\text{n.s.})\) or the left inferior parietal activation clusters \((z=0.53, p=\text{n.s.})\), suggesting that the normalisation effects in these clusters were not statistically significant.

| Post hoc group differences | Brain regions of activation differences | Brodmann area (BA) | Peak Talairach coordinates (x;y;z) | Voxels | Cluster p value |
|----------------------------|----------------------------------------|--------------------|-----------------------------------|--------|----------------|
| Placebo                    |                                        |                    |                                   |        |                |
| C < ASD                    | R inferior frontal cortex               | 44                 | 54;15;26                          | 16     | 0.03           |
| C, ADHD < ASD              | L inferior/middle frontal cortex        | 44/45/46;9         | -40;30;23                         | 82     | 0.002          |
| C, ASD > ADHD              | L STL/OFC/putamen/globus pallidus      | 38/47/11;25        | -29;11;−26                        | 73     | 0.008          |
| C > ADHD > ASD             | L inferior parietal lobe                | 40                 | -29;−22;40                        | 97     | 0.002          |
| Fluoxetine                 |                                        |                    |                                   |        |                |
| C, ASD > ADHD              | L + R pre-SMA/premotor/superior frontal cortex | 6/8             | -11;4;63                          | 203    | 0.0006         |
| C < ADHD, ASD              | SMA proper                              | 6/8/9              | -4;−11;50                         | 42     | 0.007          |
| ADHD < C < ASD             | R inferior parietal lobe/angular gyrus  | 6                  | 36;−63;30                         | 50     | 0.004          |
| C, ASD > ADHD              | L inferior parietal lobe/middle temporal | 40/39             | -47;−63;26                        | 188    | 0.0002         |
| C < ASD < ADHD             | Precuneus                               | 40/39              | 7;−67;43                          | 114    | 0.002          |

STL, superior temporal lobe; OFC, Orbitofrontal cortex, SMA, supplementary motor area
For the abnormalities in the ASD patients, however, the effect sizes for the ASD placebo-control contrast were significantly different from the effect sizes for the ASD fluoxetine-control contrast for left IFC ($z=2.8, p<0.005$) and right IFC ($z=-2.5, p<0.01$), both of which were enhanced under placebo but normalised under fluoxetine, and for left inferior parietal lobe, which was significantly reduced in ASD relative to controls under placebo, but enhanced under fluoxetine ($z=2.3, p<0.02$). The findings show that all normalisation effects in these clusters were statistically significant.

Control for IQ

To assess the potential impact of IQ on case-control group differences, all analyses were repeated with IQ as a covariate. All clusters remained at a $p<0.01$, apart from left OFC in the placebo between-group ANCOVA and right IPL in the fluoxetine between-group ANCOVA, which survived at a more lenient $p<0.05$.

Within-patients group by medication interaction effects

ANCOVA analysis with group as dependent variable and drug as within-group variable showed a significant group by medication interaction effect in five clusters. (1) Fluoxetine reduced pre-SMA activation in ADHD boys, whereas it increased it in ASD boys during successful inhibition ($p<0.005$). (2) Fluoxetine increased activation in left OFC/STL/putamen/globus pallidus in ADHD during successful inhibition relative to placebo, but reduced it in ASD ($p<0.05$). (3) Both patient groups activated left IPL during failed inhibition under placebo, but ADHD boys activated this region more during failed inhibition and ASD boys more during successful inhibition under fluoxetine ($p<0.0001$). (4) Right cerebellum activation was increased under fluoxetine in ADHD relative to placebo for successful inhibition, while ASD boys activated this area during failed inhibition under both placebo and fluoxetine ($p<0.05$). (5) At a more lenient $p<0.05$, relative to placebo, fluoxetine increased activation in the hypothesised right IFC during successful inhibition in ADHD and decreased it in ASD ($p<0.05$) (Fig. 2, Table 4). The same cluster was also confirmed by a region-of-interest analysis (Talairach coordinates $(x;y;z)=51;4;30$; BA 45; 7 voxels).

No significant correlations with performance were observed. All findings remained when IQ was covaried for.

Discussion

The findings reveal opposite brain dysfunction patterns in inhibitory brain regions in ADHD and ASD as well as opposite disorder-dissociated modulation effects of fluoxetine on these neurofunctional abnormalities. Relative to controls, ADHD patients showed reduced left OFC/basal ganglia activation, whereas ASD patients showed enhanced bilateral ventrolateral prefrontal activation relative to ADHD and controls. Fluoxetine normalized these disorder-dissociated brain abnormalities relative to controls, via disorder-dissociated opposite effects within patients: fluoxetine enhanced the abnormally reduced OFC/basal ganglia activation in ADHD, but reduced it in ASD. In contrast, it reduced the abnormally enhanced IFC activation in ASD, but enhanced it in ADHD. However, rigorous testing for the significance of these normalisation effects showed that these were only significant for the abnormality clusters in ASD. Furthermore, fluoxetine also had opposite disorder-dissociated effects on other inhibition areas such as pre-SMA and cerebellum: these were, respectively, enhanced (SMA) and reduced (cerebellum) in ADHD with fluoxetine relative to placebo, but reduced (SMA) and enhanced (cerebellum) in ASD.

The finding of disorder-specific increased activation in ASD relative to controls and ADHD in the left and right (trend-wise significant relative to ADHD) IFC extends our previous finding of increased left IFC activation in young adults with Asperger's syndrome during a go/no-go task (Schmitz et al. 2006) by demonstrating disorder-specificity relative to ADHD. Predominantly, the right (Chambers et al. 2009; Rubia et al. 2003) but also left IFC (Hampshire et al. 2010; Rubia et al. 2011; Rubia et al. 2001; Rubia et al. 2007) are crucial areas mediating response inhibition and ASD patients may have needed to recruit these areas more for comparable task performance. ADHD patients had no underactivation in these areas relative to controls, unlike observed previously (Cubillo et al. 2014; Hart et al. 2013; Rubia 2011; Rubia et al. 1999; Rubia et al. 2005b), but relative to ASD. This, and the lack of a significant difference between controls and ADHD boys in SSRT may be due to long-term effects of stimulant medication, which has been associated with more normal prefrontal and striatal function (Hart et al. 2012; Hart et al. 2013; Rubia et al. 2014), as 11 of the ADHD boys were on chronic methylphenidate medication, even if taken off medication prior to the scan. It is also interesting to note that the enhanced omission errors which were observed in ADHD patients relative to both control and ASD boys under placebo were correlated with reduced IFC-striatal activation under placebo. It has been suggested that omission errors are indicative of an alternative strategy that ADHD boys may employ to decrease their number of failed inhibitions (Tannock et al. 1989). Therefore, although there was no behavioural evidence for poor inhibitory performance using the inhibitory measure of the SSRT, there were significant differences in omission errors in ADHD patients under placebo. The differences correlated with the neurofunctional deficits and were no longer observed under
fluoxetine. The disorder-exclusive deficits in ADHD adolescents in the left OFC/basal ganglia relative to controls extend prior findings of OFC-striatal deficits in ADHD (Cubillo et al. 2014; Hart et al. 2013; Rubia 2011; Rubia et al. 1999; Rubia et al. 2005b; Rubia et al. 2014). Our results therefore show disorder-dissociated frontal lobe dysfunctions in ADHD and ASD boys during inhibition relative to controls: with ASD patients showing significantly enhanced bilateral IFC activation and ADHD boys showing significantly reduced OFC/basal ganglia activation, which furthermore correlated with their enhanced omission errors during task performance.

Fluoxetine normalized all disorder-dissociated frontal brain dysfunctions due to opposite modulation effects in both disorders, which were, however, only significant in the ASD group. Fluoxetine significantly reduced bilateral OFC activation in the ASD group but enhanced it in ADHD. Under fluoxetine, ADHD patients also no longer showed enhanced omission errors, which were reduced under placebo and correlated with the OFC deficits. Fluoxetine also had an opposite up/downregulation effect on another key inhibition region, the pre-SMA: this was upregulated in ASD and hence increased relative to controls and ADHD, but downregulated in ADHD and hence reduced relative to controls and ASD. The upregulation effect of fluoxetine on right IFC and left OFC-striatal regions in ADHD extends prior evidence on SE agonist modulation of these areas in healthy adults during inhibitory control (Del-Ben et al. 2005) to the ADHD population. Most intriguing, however, are the consistently opposite reduction effects of fluoxetine on these frontal activations in the ASD group. Opposite activation effects could possibly reflect group differences in baseline SE levels, as evidenced by lower platelet SE levels in ADHD children compared to controls (Spivak et al. 1999), and increased baseline platelet, blood and prefrontal SE levels in 30% of individuals with ASD relative to controls (Hranilovic et al. 2007; Mulder et al. 2004; Nakamura et al. 2010; Piven et al. 1991). In addition, ASD patients have abnormal 5-HT synthesis (Chugani et al. 1997), 5-HT transporter (Makkonen et al. 2008; Nakamura et al. 2010) and 5-HT2A receptor binding (Murphy et al. 2006). Therefore, fluoxetine may increase the low SE baseline of children with ADHD to normal levels, leading to normalized activation in fronto-striatal areas. Whereas in children with ASD, the increase in SE in an already hyperserotonemic system may activate a negative feedback mechanism via

### Table 4 Group by drug interaction effects within ADHD and ASD patients

| Brain regions of activation | Brodmann area (BA) | Peak Talairach coordinates (x,y,z) | Voxels | Cluster p value |
|-----------------------------|--------------------|-----------------------------------|--------|----------------|
| R inferior/middle frontal cortex | 44/9               | 51;0;26                           | 21     | 0.03           |
| R pre-SMA/premotor/superior frontal cortex | 6/8                | −7;33;56                          | 1085   | 0.0003         |
| L STL/OFC/putamen/globus pallidus | 38/47/11/25       | −4;−7;−26                         | 452    | 0.004          |
| L inferior parietal/middle/STL/occipital lobe | 39/40/22/19       | −43;−67;30                        | 237    | 0.008          |
| R cerebellum                |                    | 22;−41;−17                        | 139    | 0.0005         |

STL superior temporal lobe, OFC orbitofrontal cortex, SMA supplementary motor area
activation of 5-HT_{1A} autoreceptors (Sibley et al. 2007), leading to a decrease in SE and in fronto-striatal activation.

Despite significant modulation effects on brain activation, fluoxetine had no effect on inhibitory performance. However, the enhanced omission errors that were observed in ADHD patients under placebo relative to controls were no longer significant under fluoxetine. Furthermore, it is well-documented that brain function is more sensitive to pharmacological manipulations than inhibitory performance (Cubillo et al. 2014; Rubia et al. 2011; Rubia et al. 2005a). In addition, one of the upregulated regions in ASD in a key inhibitory area, the pre-SMA, was correlated with SSRT, suggesting a relationship between activation changes and inhibitory performance.

The strengths of this study are carefully selected and non-comorbid patient groups who had no psychiatric comorbidities and, in the case of the ASD group, were medication-naïve. A limitation of this study is that for ethical and financial reasons, the control group was scanned only once, while patients were scanned twice which could have accounted for the lack of performance differences. The significantly lower IQ in the ADHD compared to the other two groups is another limitation. However, covariance analysis showed that the findings were not affected by IQ. Furthermore, stop task performance has been shown to be independent of IQ (Friedman et al. 2006). Lastly, while the contrast of successful and unsuccessful stop trials controls for the attentional oddball effect of the low frequency of stop stimuli, it may be over-protective, as during unsuccessful stop trials subjects may also attempt, but not achieve to inhibit.

Conclusions

To summarise, ADHD and ASD patients showed opposite brain activation abnormalities relative to controls: ADHD boys showed reduced while ASD boys enhanced frontal activation. Importantly, fluoxetine had a disorder-dissociated opposite effect on frontal brain dysfunctions, enhancing frontal activation in ADHD and reducing it in ASD which could suggest differential underlying SE baseline levels in the two disorders.

Acknowledgments

This study and Dr. Andy Simmonds were supported by the UK Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) for Mental Health at South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, King’s College London. The research leading to these results has also received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no 115300, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007 - 2013) and EFPIA companies’ in kind contribution.

Funding

Katya Rubia has received a funding from Lilly for another project and speaker’s honoraria from Lilly, Shire and Novartis. Michael Brammer is a consultant for P1vital, Ltd, Oxford, UK.

Conflict of interest

The other authors have no conflict of interests to declare.

Open Access

This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

Alderson R, Rapport M, Kofer M (2007) Attention-deficit/hyperactivity disorder and behavioral inhibition: a meta-analytic review of the stop-signal paradigm. J Abnorm Child Psychol 35(5):745–758
American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington
Anderson IM, McKie S, Elliott R, Williams SR, Deakin JFW (2008) Assessing human 5-HT function in vivo with pharmacoMRI. Neuropeychopharmacology 55(6):1029–1037
Barrickman L, Noyes R, Kuperman S, Schumacher E, Verda M (1991) Treatment of ADHD with fluoxetine—a preliminary trial. J Am Acad Child Adolesc Psychiatry 30(5):762–767
Brammer MJ, Bullmore ET, Simmons A, Williams SCR, Grasby PM, Howard RJ et al (1997) Generic brain activation mapping in functional magnetic resonance imaging: a nonparametric approach. Magn Reson Imaging 15(7):763–770
Bridget DJ, Walker ME (2006) Intellectual functioning in adults with ADHD: a meta-analytic examination of full scale IQ differences between adults with and without ADHD. Psychol Assess 18(1):1
Bullmore E, Brammer M, Rabe-Hesketh S, Curtis V, Morris R, Williams S et al (1999a) Methods for diagnosis and treatment of stimulus-correlated motion in generic brain activation studies using fMRI. Hum Brain Mapp 7(1):38–48
Bullmore E, Long C, Suckling J, Fadili J, Calvert G, Zelaya F et al (2001) Colored noise and computational inference in neurophysiological (fMRI) time series analysis: resampling methods in time and wavelet domains. Hum Brain Mapp 12(2):61–78
Bullmore ET, Suckling J, Overmeyer S, Rabe-Hesketh S, Taylor E, Brammer MJ (1999b) Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain. IEEE Trans Med Imaging 18(1):32–42
Chamberlain SR, Muller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ (2006) Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 311(5762):861–863
Chambers CD, Garavan H, Bellgrove MA (2009) Insights into the neural basis of response inhibition from cognitive and clinical neuroscience. Neurosci Biobehav Rev 33(5):631–646
Chugani HC, Muzik O, Rothermel R, Behen M, Chakraborty P, Mangner T et al (1997) Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Ann Neurol 42(4):666–669
Conners CK, Sitarenios G, Parker JDA, Epstein JN (1998) Revision and restandardization of the Conners' Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 26(4):279–291
Corbett BA, Constantine LJ, Hendren R, Rocke D, Ozonoff S (2009) Examining executive functioning in children with autism spectrum disorder, attention deficit hyperactivity disorder and typical development. Psychiatry Res 166(2-3):210–222
Cortese S, Kelly C, Chabernaud C, Proal E, Di Martino A, Milham MP et al (2012) Toward systems neuroscience of ADHD: a meta-analysis of 55 IMRI studies. Am J Psychiatry 169(10):1038–1055
experimental animals and humans. Handbook of Behavioral Neuroscience. Elsevier. Volume 21, pp 415–427
Robinson S, Goddard L, Dritschel B, Wisley M, Howlin P (2009) Executive functions in children with autism spectrum disorders. Brain Cogn 71(3):362–368
Rommel N, Franke B, Geurts HM, Hartman CA, Buitelaar JK (2010) Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder. Eur Child Adolesc Psychiatry 19(3):281–295
Rommel N, Geurts HM, Franke B, Buitelaar JK, Hartman CA (2011) A review on cognitive and brain endophenotypes that may be common in autism spectrum disorder and attention-deficit/hyperactivity disorder and facilitate the search for pleiotropic genes. Neurosci Biobehav Rev 35(6):1363–1396
Rubia K (2011) “Cool” inferior frontostriatal dysfunction in attention-deficit/hyperactivity disorder versus “hot” ventromedial orbitofrontal-limbic dysfunction in conduct disorder: a review. Biol Psychiatry 69(12):69–87
Rubia K, Alegria A, Brinon H (2014) Imaging the ADHD brain: disorder-specificity, medication effects and clinical translation. Expert Rev Neurother 14(5):519–538
Rubia K, Halari R, Mohammad A-M, Taylor E, Brammer M (2011) Methylphenidate normalizes frontocingulate underactivation during error processing in attention-deficit/hyperactivity disorder. Biol Psychiatry 70(3):255–262
Rubia K, Lee F, Cleare AJ, Tunstall N, Fu CHY, Brammer M et al (2005a) Tryptophan depletion reduces right inferior prefrontal activation during response inhibition in fast, event-related fMRI. Psychopharmacology (Berl) 179(4):791–803
Rubia K, Overmeyer S, Taylor E, Brammer M, Williams SCR, Simmons A et al (1999) Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. Am J Psychiatry 156(6):891–896
Rubia K, Russell T, Overmeyer S, Brammer MJ, Bullmore ET, Sharma T et al (2001) Mapping motor inhibition: conjunctive brain activations across different versions of go/no-go and stop tasks. Neuroimage 13(2):250–261
Rubia K, Smith AB, Brammer MJ, Taylor E (2003) Right inferior prefrontal cortex mediates response inhibition while mesial prefrontal cortex is responsible for error detection. Neuroimage 20(1):351–358
Rubia K, Smith AB, Brammer MJ, Toone B, Taylor E (2005b) Abnormal brain activation during inhibition and error detection in medication-naive adolescents with ADHD. Am J Psychiatry 162(6):1067–1075
Rubia K, Smith AB, Taylor E, Brammer M (2007) Linear age-correlated functional development of right inferior fronto-striato-cerebellar networks during response inhibition and anterior cingulate during error-related processes. Hum Brain Mapp 28:1163–1177
Rutter M, Bailey A, Lord C (2003) The social communication questionnaire: manual western psychological services: Los Angeles
Schmitz N, Rubia K, Daly E, Smith A, Williams S, Murphy DGM (2006) Neural correlates of executive function in autistic spectrum disorders. Biol Psychiatry 59(1):7–16
Sibley D, Hanin I, Kuhar M, Skolnick P (2007) Handbook of Contemporary Neuropharmacology Vol. 1. Wiley Blackwell, New York
Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G (2008) Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 47(8):921–929
Sinzig J, Lehmkuhl G (2007) What do we know about the serotonergic genetic heterogeneity in attention-deficit/hyperactivity and autistic disorders? Psychopathology 40(5):329–337
Spivak B, Vered Y, Yoran-Hegesh R, Averbuch E, Mester R, Graf E et al (1999) Circulatory levels of catecholamines, serotonin and lipids in attention deficit hyperactivity disorder. Acta Psychiatr Scand 99(4):300–304
Tannock R, Schachar R, Carr R, Chajczyk D, Logan G (1989) Effects of methylphenidate on inhibitory control in hyperactive children. J Abnorm Child Psychol 17(5):473–491
Thirion B, Pinel P, Meriaux S, Roche A, Dehaene S, Poline JB (2007) Analysis of a large fMRI cohort: statistical and methodological issues for group analyses. Neuroimage 35(1):105–120
van der Meer JMJ, Oerlemans AM, van Steijn DJ, Lappenschaar MGA, de Sonneville LMJ, Buitelaar JK et al (2012) Are autism spectrum disorder and attention-deficit/hyperactivity disorder different manifestations of one overarching disorder? Cognitive and symptom evidence from a clinical and population-based sample. J Am Acad Child Adolesc Psychiatry 51(11):1160–1172
Wechsler D (1999) Wechsler Abbreviated Scale of Intelligence. The Psychological Corporation, San Antonio
Wong DT, Bymaster FP, Engleman EA (1995) Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: 20 years since its first publication. Life Sci 57(5):411–441
World Health Organisation (1994) ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organisation, Geneva
Zafeiriou DI, Ververi A, Vargianni E (2009) The serotonergic system: its role in pathogenesis and early developmental treatment of autism. Curr Neuropharmacol 7(2):150–157